KDM1A and small cell lung carcinoma: Another TCP derived LSD1 inhibitor, ORY-1001 (Iadademstat), has been demonstrated to be safe in a phase 1 trial and is currently in phase 2 clinical trials (NCT05420636) in combination with paclitaxel, an antineoplastic drug, in small cell lung cancer and neuroendocrine carcinoma to determine response rate (88).